Tailored therapy of colorectal cancer: Results, challenges and future directions

Giampietro Gasparini, Raffaele Longo, Carlo Barone, Giuseppe Toffoli

Research output: Contribution to journalArticle

Abstract

Colorectal cancer is a leading cause of cancer mortality and morbidity. Despite the recent results of systemic chemotherapy, more than 40% of patients with advanced cancer still do not achieve substantial benefits with cytotoxic agents. Therefore, new tailored strategies are warranted to improve the probability of disease control. The rationale for this approach is based on the identification of the in vivo interactions among patient's characteristics, disease physiopathology, and drug pharmacodynamics and pharmacokinetics. Genomic and proteomic technologies may clarify the mechanisms involved in cancer growth and progression in each single patient and in the molecular basis of interindividual differences of anticancer drugs in terms of efficacy and toxicity. Despite the recent encouraging data, the clinical use of targeted therapy is hampered by several questions, such as: optimal biologic dose and schedule, lack of predictive surrogate biomarkers, and modalities of combination with chemotherapy/radiotherapy. Further efforts are needed to improve the reliability of genomic and proteomic technologies, in particular regarding their standardization and widespread availability. These unsolved issues make tailored therapy an open challenge.

Original languageEnglish
Pages (from-to)175-188
Number of pages14
JournalCancer Journal (United States)
Volume11
Issue number3
Publication statusPublished - 1998

Fingerprint

Colorectal Neoplasms
Proteomics
Technology
Neoplasms
Cytotoxins
Combination Drug Therapy
Pharmaceutical Preparations
Appointments and Schedules
Radiotherapy
Therapeutics
Pharmacokinetics
Biomarkers
Morbidity
Drug Therapy
Mortality
Growth
Direction compound

Keywords

  • Colorectal cancer
  • Molecular-targeting treatments
  • Personalized therapy
  • Tailored therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tailored therapy of colorectal cancer : Results, challenges and future directions. / Gasparini, Giampietro; Longo, Raffaele; Barone, Carlo; Toffoli, Giuseppe.

In: Cancer Journal (United States), Vol. 11, No. 3, 1998, p. 175-188.

Research output: Contribution to journalArticle

Gasparini, Giampietro ; Longo, Raffaele ; Barone, Carlo ; Toffoli, Giuseppe. / Tailored therapy of colorectal cancer : Results, challenges and future directions. In: Cancer Journal (United States). 1998 ; Vol. 11, No. 3. pp. 175-188.
@article{41733342e2d046b4850bbc100e44d904,
title = "Tailored therapy of colorectal cancer: Results, challenges and future directions",
abstract = "Colorectal cancer is a leading cause of cancer mortality and morbidity. Despite the recent results of systemic chemotherapy, more than 40{\%} of patients with advanced cancer still do not achieve substantial benefits with cytotoxic agents. Therefore, new tailored strategies are warranted to improve the probability of disease control. The rationale for this approach is based on the identification of the in vivo interactions among patient's characteristics, disease physiopathology, and drug pharmacodynamics and pharmacokinetics. Genomic and proteomic technologies may clarify the mechanisms involved in cancer growth and progression in each single patient and in the molecular basis of interindividual differences of anticancer drugs in terms of efficacy and toxicity. Despite the recent encouraging data, the clinical use of targeted therapy is hampered by several questions, such as: optimal biologic dose and schedule, lack of predictive surrogate biomarkers, and modalities of combination with chemotherapy/radiotherapy. Further efforts are needed to improve the reliability of genomic and proteomic technologies, in particular regarding their standardization and widespread availability. These unsolved issues make tailored therapy an open challenge.",
keywords = "Colorectal cancer, Molecular-targeting treatments, Personalized therapy, Tailored therapy",
author = "Giampietro Gasparini and Raffaele Longo and Carlo Barone and Giuseppe Toffoli",
year = "1998",
language = "English",
volume = "11",
pages = "175--188",
journal = "Cancer Journal from Scientific American",
issn = "1528-9117",
publisher = "Association Pour le Developpement de la Communication Cancerologique",
number = "3",

}

TY - JOUR

T1 - Tailored therapy of colorectal cancer

T2 - Results, challenges and future directions

AU - Gasparini, Giampietro

AU - Longo, Raffaele

AU - Barone, Carlo

AU - Toffoli, Giuseppe

PY - 1998

Y1 - 1998

N2 - Colorectal cancer is a leading cause of cancer mortality and morbidity. Despite the recent results of systemic chemotherapy, more than 40% of patients with advanced cancer still do not achieve substantial benefits with cytotoxic agents. Therefore, new tailored strategies are warranted to improve the probability of disease control. The rationale for this approach is based on the identification of the in vivo interactions among patient's characteristics, disease physiopathology, and drug pharmacodynamics and pharmacokinetics. Genomic and proteomic technologies may clarify the mechanisms involved in cancer growth and progression in each single patient and in the molecular basis of interindividual differences of anticancer drugs in terms of efficacy and toxicity. Despite the recent encouraging data, the clinical use of targeted therapy is hampered by several questions, such as: optimal biologic dose and schedule, lack of predictive surrogate biomarkers, and modalities of combination with chemotherapy/radiotherapy. Further efforts are needed to improve the reliability of genomic and proteomic technologies, in particular regarding their standardization and widespread availability. These unsolved issues make tailored therapy an open challenge.

AB - Colorectal cancer is a leading cause of cancer mortality and morbidity. Despite the recent results of systemic chemotherapy, more than 40% of patients with advanced cancer still do not achieve substantial benefits with cytotoxic agents. Therefore, new tailored strategies are warranted to improve the probability of disease control. The rationale for this approach is based on the identification of the in vivo interactions among patient's characteristics, disease physiopathology, and drug pharmacodynamics and pharmacokinetics. Genomic and proteomic technologies may clarify the mechanisms involved in cancer growth and progression in each single patient and in the molecular basis of interindividual differences of anticancer drugs in terms of efficacy and toxicity. Despite the recent encouraging data, the clinical use of targeted therapy is hampered by several questions, such as: optimal biologic dose and schedule, lack of predictive surrogate biomarkers, and modalities of combination with chemotherapy/radiotherapy. Further efforts are needed to improve the reliability of genomic and proteomic technologies, in particular regarding their standardization and widespread availability. These unsolved issues make tailored therapy an open challenge.

KW - Colorectal cancer

KW - Molecular-targeting treatments

KW - Personalized therapy

KW - Tailored therapy

UR - http://www.scopus.com/inward/record.url?scp=33749568809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749568809&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 175

EP - 188

JO - Cancer Journal from Scientific American

JF - Cancer Journal from Scientific American

SN - 1528-9117

IS - 3

ER -